Reviewer’s report

Title: Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France

Version: 1 Date: 14 October 2012

Reviewer: Tomohiko Shimatani

Reviewer’s report:

In this manuscript, the authors presented the results of the REMAIN France study, i.e., the treatment pathways, resource utilization, costs, symptoms and HRQL in European patients with GERD who were newly identified as partial responders to optimized PPI therapy. The study was uniquely performed and the results were well discussed. The reviewer considered that no serious problems were found, however, it contains some questions as follows.

1) Were the results of this study different between proton pump inhibitor users and other drug users?
2) Do the doses of proton pump inhibitors, i.e., half dose or full dose, affect these results?

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

None declared.